Amplia and ANZGOG announce Ovarian Cancer Study
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Amplia Therapeutics Ltd. and ANZGOG have announced a new clinical study focused on ovarian cancer, specifically evaluating the drug narmafotinib in combination with standard chemotherapy. The study aims to enroll patients with high-grade serous ovarian cancer who have not responded to initial chemotherapy, addressing a significant unmet medical need. This investigator-initiated trial will explore the safety of narmafotinib and its potential to improve surgical outcomes for these patients. The trial is expected to provide insights into narmafotinib's mechanism of action through extensive biomarker collection.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Amplia Therapeutics Ltd. on 6ix
Story so far
Earlier from Amplia Therapeutics
- Accent Trial Mature Data Presented at International Conference
- Amplia Therapeutics Halts Recruitment in AMPLICITY Trial
- Amplia Therapeutics Reports Four Additional Complete Responses and Improved Overall Survival Data in Accent Pancreatic Cancer Trial
- Amplia Reports Improved Responses & Survival in ACCENT trial
- Trading Halt
Later from Amplia Therapeutics
- Amplia Therapeutics and Australia New Zealand Gynaecological Oncology Group (Anzgog) Announce Ovarian Cancer Study
- Amplia Launches First Stage of Pivotal Narmafotinib Trial
- Amplia Therapeutics Launches First Stage of Registration-Enabling Trial of Narmafotinib
- Preliminary Final Report and Annual Report YE 31 March 2026
- Following Significant Advances at ASCO, Amplia Therapeutics Provides Letter to Shareholders Highlighting the Potential Opportunities for Combination with KRAS Inhibition in Pancreatic Cancer
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics